Schizophrenia: Clinical Features, Diagnosis, Treatment and Long-Term Care
Schizophrenia is a serious, treatable mental disorder involving a characteristic combination of psychotic symptoms, negative symptoms, cognitive difficulties, altered mood and functional impairment. It is not “split personality,” a moral failure or a life sentence without recovery. Early, respectful, continuous care can reduce relapse, disability, suicide risk and physical-health inequality.
Learning objectives
- Describe positive, negative, cognitive, affective and psychomotor features of schizophrenia.
- Differentiate schizophrenia from mood, substance-induced, delirium and medical/neurological psychoses.
- Complete a comprehensive first-episode and relapse assessment.
- Plan pharmacological, psychological, family, social and physical-health care.
- Monitor treatment, manage adverse effects and build relapse prevention.
1. Clinical domains
| Domain | Examples | Clinical impact |
|---|---|---|
| Positive symptoms | Delusions, hallucinations, disorganised speech and behaviour | Distress, risk, impaired judgement and social disruption |
| Negative symptoms | Avolition, anhedonia, alogia, blunted affect and social withdrawal | Loss of function, employment, relationships and self-care |
| Cognition | Attention, working memory, processing speed and executive dysfunction | Learning, planning, adherence and independent living difficulties |
| Affective symptoms | Depression, anxiety, irritability, hopelessness and emotional dysregulation | Suicide risk, substance use and relapse vulnerability |
| Psychomotor/catatonia | Agitation, retardation, posturing, mutism, stupor or stereotypies | Medical complications and emergency risk |
2. Course and phases
- Prodrome: social withdrawal, sleep change, reduced function, suspiciousness, declining self-care or unusual experiences.
- First episode: clear psychosis with marked distress or functional decline; early treatment can improve outcome.
- Acute phase: positive symptoms and risk require active treatment, sometimes admission.
- Recovery/stabilisation: symptoms reduce; titrate treatment, restore function and address adverse effects.
- Maintenance: prevent relapse, maintain physical health, social roles and recovery goals.
3. Diagnostic assessment
- Establish symptoms, onset, duration, mood relationship, function, trauma, substances, medicines and previous episodes.
- Obtain collateral history to define baseline, timeline, adherence, sleep, risk and functioning.
- Perform physical and neurological examination, vitals, glucose, movement examination and pregnancy assessment where relevant.
- Investigate medical/substance mimics, especially at first episode or with red flags.
- Document a longitudinal formulation and provisional diagnosis when duration or exclusion remains uncertain.
4. Differential diagnosis
| Condition | Clues |
|---|---|
| Schizoaffective disorder | Prominent mood episodes plus a period of psychosis outside mood episodes. |
| Bipolar mania with psychosis | Elevated/irritable mood, reduced need for sleep, high energy, grandiosity and episodic course. |
| Psychotic depression | Severe depressive syndrome and psychosis during the mood episode. |
| Substance/medication-induced psychosis | Symptoms closely linked to intoxication, withdrawal or a medicine; reassess when sober/stable. |
| Delirium/medical psychosis | Fluctuating attention, altered consciousness, abnormal vitals, seizures, focal signs or atypical onset. |
| Delusional disorder | Persistent delusion with relatively preserved functioning and little pervasive disorganisation. |
5. Risk assessment
- Suicide: hopelessness, depression, command voices, substance use, previous attempts, recent discharge and access to means.
- Violence: threats, persecutory beliefs, command hallucinations, intoxication, weapons, impulsivity and past violence.
- Self-neglect: food/fluid refusal, homelessness, untreated medical illness, inability to obtain medicines or severe disorganisation.
- Vulnerability: abuse, exploitation, coercive relationships, financial harm and risk to children or dependants.
Use a collaborative, least-restrictive safety plan. Admission or urgent specialist care may be needed when risk cannot be safely managed in the community.
6. Physical-health assessment
- Baseline weight/BMI, waist, pulse, blood pressure, glucose/HbA1c, lipids, smoking, alcohol/substances and movement examination.
- ECG when cardiac history, syncope, QT-risk medicine, overdose, electrolyte abnormality or antipsychotic indication warrants it.
- FBC, electrolytes/renal/liver function, thyroid, pregnancy test and HIV/syphilis or other infection tests guided by presentation and local policy.
- Assess cardiovascular risk, diabetes, respiratory disease, oral health, sexual/reproductive health, HIV/TB care and access to exercise/nutritious food.
7. Antipsychotic treatment
Offer one antipsychotic after shared discussion of benefits, adverse effects, previous response, route, cost, pregnancy, metabolic and cardiac risks. Start low and titrate gradually. Avoid routine polypharmacy and document the target symptoms and review date.
| Medicine | Common adult educational range | High-yield cautions |
|---|---|---|
| Risperidone | Start 0.5–1 mg/day; usual 2–6 mg/day | EPS, akathisia, prolactin, orthostasis and renal dosing. |
| Olanzapine | Start 5–10 mg/day; usual 10–20 mg/day | Weight gain, diabetes, dyslipidaemia and sedation; smoking alters levels. |
| Quetiapine | Titrate gradually; common range 150–800 mg/day | Sedation, orthostasis, metabolic effects and QT risk. |
| Aripiprazole | Usually 10–15 mg/day; common range 10–30 mg/day | Akathisia, insomnia and impulse-control problems; lower metabolic burden. |
| Haloperidol | Often 0.5–5 mg/day initially; higher specialist doses may be used | EPS, dystonia, QT prolongation and NMS. |
| Clozapine | Start 12.5 mg once/twice daily and titrate slowly; many need 200–450 mg/day | Treatment resistance or persistent suicidality under specialist FBC/ANC and medical monitoring. |
8. Monitoring and adverse effects
- Review response, adherence, sedation, orthostasis, akathisia, dystonia, parkinsonism, tardive movements and suicidality.
- Monitor weight/BMI, waist, BP, glucose/HbA1c, lipids, smoking and physical activity.
- Ask about prolactin symptoms: amenorrhoea, galactorrhoea, sexual dysfunction and infertility.
- Teach warning signs of NMS, severe rash, myocarditis, agranulocytosis and clozapine constipation/ileus.
- Do not mistake akathisia for worsening psychosis or increase the dose reflexively.
9. Treatment resistance and clozapine
Confirm diagnosis, adherence, dose, duration, substance use, interactions and adequate trials before labelling treatment resistance. Clozapine is considered after persistent symptoms despite adequate trials of two antipsychotics or in selected persistent suicidality. It requires a specialist programme, blood-count monitoring, constipation prevention and education about fever, sore throat, infection, chest pain, breathlessness, seizures and smoking changes.
10. Long-acting injectable antipsychotics
Long-acting injections can reduce missed doses and provide predictable exposure when the patient prefers them or adherence has been difficult. Confirm oral tolerability, explain injection-site effects, product-specific loading/oral overlap, missed-dose plans, pregnancy considerations and the difficulty of rapidly reversing adverse effects. Consent and shared decision-making are essential.
11. Psychosocial and recovery interventions
- Family psychoeducation, communication training and an early-warning plan.
- CBT for psychosis to reduce distress and improve coping.
- Supported employment/education, occupational therapy, social skills and rehabilitation.
- Substance-use treatment, sleep/routine stabilisation, exercise and smoking cessation.
- Peer support, housing, social protection, legal/safeguarding referrals and culturally responsive care.
12. Relapse prevention
Identify the patient’s early warning signs: reduced sleep, social withdrawal, suspiciousness, voices, disorganised speech, substance escalation, missed doses or unusual spending. Write a plan naming trusted contacts, crisis services, medicine support, means safety and thresholds for urgent review. Review after discharge early and regularly.
13. Special situations
- Pregnancy/postpartum: balance relapse risk and medicine risk with specialist obstetric/psychiatric care; assess postpartum psychosis urgently.
- HIV/TB: review interactions, adherence, opportunistic disease and neurocognitive symptoms.
- Older age/Parkinsonism: start low, go slowly and avoid dopamine blockers where possible.
- Substance use: treat intoxication/withdrawal and psychosis together; do not assume symptoms will resolve without follow-up.
14. Worked cases
First episode
A 20-year-old has voices, social withdrawal and poor sleep for two months. Complete collateral, risk, physical/neurological, substance and baseline investigations; begin coordinated early-psychosis care while refining the diagnosis.
Akathisia mistaken for relapse
A patient paces constantly after risperidone increase and reports unbearable restlessness. Assess suicidality, review dose and consider a safer adjustment rather than escalating antipsychotic treatment.
Relapse after stopping medicine
A patient becomes suspicious and sleepless after stopping tablets due to sexual side effects. Listen without blame, address the adverse effect, discuss alternatives or long-acting treatment and update the relapse plan.
15. Quick self-test
- Name the five main clinical domains of schizophrenia.
- What must be excluded in first-episode psychosis?
- List baseline physical-health measures before antipsychotics.
- When is clozapine considered?
- Why can akathisia be dangerous?
- Name four psychosocial interventions.
- What should a relapse plan contain?
Answers
- Positive, negative, cognitive, affective and psychomotor/catatonic domains.
- Delirium, substances/medicines, medical and neurological disease, mood disorders, seizures, infection and other causes.
- Weight/BMI, waist, pulse/BP, glucose/HbA1c, lipids, movement exam, cardiac history/ECG when indicated and relevant renal/liver/pregnancy tests.
- Persistent symptoms despite adequate trials of two antipsychotics or selected persistent suicidality under specialist monitoring.
- Severe inner restlessness can be mistaken for relapse and may increase distress, impulsivity and suicide risk.
- Family work, CBT for psychosis, supported employment/education, rehabilitation, substance-use treatment, peer support and relapse planning.
- Early warning signs, trusted contacts, medicines, crisis pathways, means safety, follow-up and escalation thresholds.
References
- NICE: Psychosis and schizophrenia in adults.
- WHO mhGAP Intervention Guide.
- WHO mhGAP guideline 2023.
- WHO ICD-11 clinical descriptions and diagnostic requirements.
- Use Uganda Ministry of Health and hospital protocols for medicines, emergency sedation, safeguarding, referral and physical-health monitoring.
